HK1166989A1 - Binding member for gm-csf receptor gm-csf - Google Patents

Binding member for gm-csf receptor gm-csf

Info

Publication number: HK1166989A1
Authority: HK; Hong Kong
Prior art keywords: csf; receptor; binding member; binding members; csfr
Prior art date: 2006-03-27

Application number

HK12107671.7A

Other languages

English (en)

Inventor

Emma Cohen

Ralph Minter

Paula Harrison

Matthew Sleeman

Andrew Nash

Louis Fabri

Original Assignee

Medimmune Ltd

Zenyth Operations Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-27

Filing date

2012-08-03

Publication date

2012-11-16

2012-08-03 Application filed by Medimmune Ltd, Zenyth Operations Pty Ltd filed Critical Medimmune Ltd

2012-11-16 Publication of HK1166989A1 publication Critical patent/HK1166989A1/xx

Links

102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 3
102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 title 1
108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 title 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
208000025113 myeloid leukemia Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Oncology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)

HK12107671.7A 2006-03-27 2012-08-03 Binding member for gm-csf receptor gm-csf HK1166989A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US78656906P	2006-03-27	2006-03-27

Publications (1)

Publication Number	Publication Date
HK1166989A1 true HK1166989A1 (en)	2012-11-16

Family

ID=38293698

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK12107633.4A HK1166988A1 (en)	2006-03-27	2012-08-02	Binding member for gm-csf receptor gm-csf
HK12107671.7A HK1166989A1 (en)	2006-03-27	2012-08-03	Binding member for gm-csf receptor gm-csf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK12107633.4A HK1166988A1 (en)	2006-03-27	2012-08-02	Binding member for gm-csf receptor gm-csf

Country Status (16)

Country	Link
US (8)	US8506960B2 (xx)
EP (3)	EP2423229B1 (xx)
JP (2)	JP5335662B2 (xx)
KR (2)	KR101451546B1 (xx)
CN (3)	CN101443360B (xx)
BR (1)	BRPI0709259B1 (xx)
CA (1)	CA2647449C (xx)
DK (3)	DK2423230T3 (xx)
ES (3)	ES2395839T3 (xx)
HK (2)	HK1166988A1 (xx)
MX (2)	MX2008012291A (xx)
PL (3)	PL2423230T3 (xx)
PT (3)	PT1999152E (xx)
RU (2)	RU2495050C2 (xx)
SI (3)	SI1999152T1 (xx)
WO (1)	WO2007110631A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2423230T3 (pl) *	2006-03-27	2013-10-31	Medimmune Ltd	Element wiążący dla receptora GM-CSF
MX2009005398A (es)	2006-11-21	2009-08-20	Kalobios Pharmaceuticals Inc	Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
US8075885B2 (en)	2008-04-07	2011-12-13	Kalobios Pharmaceuticals, Inc.	Methods of treating heart failure using an anti-GM-CSF antibody
AU2015224416B2 (en) *	2008-12-22	2017-04-20	The University Of Melbourne	Osteoarthritis treatment
RU2630969C2 (ru)	2008-12-22	2017-09-15	Де Юниверсити Оф Мельбурн	Лечение боли
ES2886063T3 (es) *	2008-12-22	2021-12-16	Univ Melbourne	Tratamiento de la artrosis
US8609101B2 (en)	2009-04-23	2013-12-17	Theraclone Sciences, Inc.	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
KR20120011883A (ko) *	2009-05-05	2012-02-08	모르포시스 아게	다발성 경화증의 치료
US20120165220A1 (en) *	2009-09-03	2012-06-28	Colgan Sean P	Uses of CD116 Expression Level
AU2012322991B2 (en) *	2011-10-10	2018-02-15	Medimmune Limited	Treatment for rheumatoid arthritis
KR20140103122A (ko) *	2011-11-17	2014-08-25	넨키 인스티튜트 오브 익스페리멘탈 바이올로지	신경교종을 치료하기 위한 조성물 및 방법
EP2602264A1 (en)	2011-12-05	2013-06-12	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH	GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en)	2011-12-22	2013-06-27	Csl Limited	Method of treating inflammatory bowel disease
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en)	2012-10-31	2014-05-08	Takeda Gmbh	Lyophilized formulation comprising gm-csf neutralizing compound
PL2932264T3 (pl) *	2012-12-14	2019-09-30	Biontech Rna Pharmaceuticals Gmbh	Nowe niezależne od MHC antygeny powiązane z nowotworem
CN103193882B (zh) *	2013-03-29	2014-11-05	浙江大学	胚胎干细胞特异性标志物GM-CSFRα及其应用
WO2015028657A1 (en)	2013-08-30	2015-03-05	Takeda Gmbh	Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
JP6769879B2 (ja)	2014-05-07	2020-10-14	タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａＧｍｂＨ	Ｇｍ−ｃｓｆ中和化合物を含む液体製剤
JP2017515828A (ja) *	2014-05-19	2017-06-15	メディミューンリミテッド	関節リウマチのための治療
GB201503139D0 (en) *	2015-02-25	2015-04-08	Univ Leicester	Diagnostic and therapeutic target
GB201519331D0 (en) *	2015-11-02	2015-12-16	Glaxosmithkline Ip Dev Ltd	Treatment paradigm
AU2017270027B2 (en)	2016-05-24	2024-07-11	Medimmune Limited	Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
EP3797792A1 (en)	2017-03-01	2021-03-31	MedImmune Limited	Formulations of anti-gm-csfralpha monoclonal antibody
US11655293B2 (en)	2018-02-22	2023-05-23	Universitat Zurich	Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en)	2018-09-14	2020-03-18	Universität Zürich	Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en)	2018-10-17	2021-08-03	University Of Connecticut	Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en)	2018-11-09	2020-05-14	Kiniksa Pharmaceuticals, Ltd.	Treatment for giant cell arteritis
US20220010007A1 (en)	2018-11-09	2022-01-13	Kiniksa Pharmaeuticals, Ltd.	Treatment for Giant Cell Arteritis
US20230002496A1 (en) *	2018-11-27	2023-01-05	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
JP2022535062A (ja)	2019-06-03	2022-08-04	キニクサファーマシューティカルズ，リミテッド	Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
US20230030680A1 (en) *	2020-01-07	2023-02-02	St. Jude Children's Research Hospital, Inc	Chimeric gmcsf-il18 receptor
WO2021188409A1 (en) *	2020-03-15	2021-09-23	Kiniksa Pharmaceuticals, Ltd.	Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en)	2020-04-06	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) *	2020-05-25	2020-09-22	北京大学	一种抗gm-csf纳米抗体及其制备方法和应用
KR20230095983A (ko) *	2020-10-26	2023-06-29	키닉사 파마슈티컬스, 리미티드	Gm-csf 길항제를 사용한 암의 치료
EP4263597A2 (en)	2020-12-18	2023-10-25	Kiniksa Pharmaceuticals, Ltd.	Protein compositions and methods for producing and using the same
WO2023138499A1 (zh) *	2022-01-20	2023-07-27	舒泰神（北京）生物制药股份有限公司	一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5629283A (en) *	1989-08-11	1997-05-13	Amrad Corporation Limited	Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
ATE161883T1 (de) *	1989-08-11	1998-01-15	Amrad Corp Ltd	Rezeptor für granulozyten-macrophagen- koloniestimulierungsfaktor und seine derivate
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5747032A (en)	1990-08-10	1998-05-05	Amrad Corporation Limited	Monoclonal antibody to human granulocyte macrophage colony stimulating factor
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
WO1994011404A1 (en) *	1992-11-19	1994-05-26	Dana-Farber Cancer Institute	Antibodies for gm-csf receptor and uses thereof
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPN780096A0 (en) *	1996-01-30	1996-02-22	Medvet Science Pty. Ltd.	Cytokine antagonists and agonists
ES2329959T5 (es)	1998-12-10	2013-12-18	Bristol-Myers Squibb Company	Armazones de proteína para miméticos de anticuerpo y otras proteínas de unión
GB2361704C (en)	2000-03-03	2006-08-02	Cambridge Antibody Tech	Human antibodies against eotaxin and their use
US7108852B2 (en) *	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
EP2298809A3 (en)	2001-07-12	2012-02-15	FOOTE, Jefferson	Super humanized antibodies
KR100453877B1 (ko) *	2001-07-26	2004-10-20	메덱스젠 주식회사	연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CN101824090B (zh) *	2002-06-14	2013-01-02	免疫医疗公司	人源化单克隆抗体hPAM4
US7169904B2 (en) *	2002-12-17	2007-01-30	Emd Lexigen Research Center Corp.	Immunocytokine sequences and uses thereof
US20040146486A1 (en) *	2003-01-24	2004-07-29	Juan Sun	Hybrid vector system for use as a vaccine
PL2423230T3 (pl) *	2006-03-27	2013-10-31	Medimmune Ltd	Element wiążący dla receptora GM-CSF
US9209965B2 (en)	2014-01-14	2015-12-08	Microsemi Semiconductor Ulc	Network interface with clock recovery module on line card

2007
- 2007-03-27 PL PL11167923T patent/PL2423230T3/pl unknown
- 2007-03-27 PT PT77129633T patent/PT1999152E/pt unknown
- 2007-03-27 CA CA2647449A patent/CA2647449C/en active Active
- 2007-03-27 ES ES07712963T patent/ES2395839T3/es active Active
- 2007-03-27 SI SI200731100T patent/SI1999152T1/sl unknown
- 2007-03-27 KR KR1020137029959A patent/KR101451546B1/ko active IP Right Grant
- 2007-03-27 ES ES11167912T patent/ES2424467T3/es active Active
- 2007-03-27 MX MX2008012291A patent/MX2008012291A/es active IP Right Grant
- 2007-03-27 CN CN2007800154169A patent/CN101443360B/zh active Active
- 2007-03-27 CN CN201310562197.3A patent/CN103641916A/zh active Pending
- 2007-03-27 DK DK11167923.9T patent/DK2423230T3/da active
- 2007-03-27 DK DK11167912.2T patent/DK2423229T3/da active
- 2007-03-27 EP EP11167912.2A patent/EP2423229B1/en active Active
- 2007-03-27 PT PT111679122T patent/PT2423229E/pt unknown
- 2007-03-27 PT PT111679239T patent/PT2423230E/pt unknown
- 2007-03-27 KR KR20087026232A patent/KR101481844B1/ko active IP Right Grant
- 2007-03-27 EP EP07712963A patent/EP1999152B1/en active Active
- 2007-03-27 EP EP11167923.9A patent/EP2423230B1/en active Active
- 2007-03-27 SI SI200731285T patent/SI2423229T1/sl unknown
- 2007-03-27 CN CN201310558011.7A patent/CN103641915B/zh active Active
- 2007-03-27 DK DK07712963.3T patent/DK1999152T3/da active
- 2007-03-27 RU RU2008137763/10A patent/RU2495050C2/ru active
- 2007-03-27 US US12/294,616 patent/US8506960B2/en active Active
- 2007-03-27 ES ES11167923T patent/ES2424468T3/es active Active
- 2007-03-27 JP JP2009502208A patent/JP5335662B2/ja active Active
- 2007-03-27 PL PL11167912T patent/PL2423229T3/pl unknown
- 2007-03-27 US US11/692,008 patent/US8263075B2/en active Active
- 2007-03-27 WO PCT/GB2007/001108 patent/WO2007110631A1/en active Application Filing
- 2007-03-27 BR BRPI0709259-8A patent/BRPI0709259B1/pt active IP Right Grant
- 2007-03-27 MX MX2015007466A patent/MX348827B/es unknown
- 2007-03-27 SI SI200731286T patent/SI2423230T1/sl unknown
- 2007-03-27 PL PL07712963T patent/PL1999152T3/pl unknown
2012
- 2012-08-02 HK HK12107633.4A patent/HK1166988A1/xx unknown
- 2012-08-03 HK HK12107671.7A patent/HK1166989A1/xx unknown
- 2012-12-26 RU RU2012157042A patent/RU2639546C2/ru active
2013
- 2013-01-10 JP JP2013002623A patent/JP5665894B2/ja active Active
- 2013-07-12 US US13/941,409 patent/US9085628B2/en active Active
2015
- 2015-06-29 US US14/753,792 patent/US20150376285A1/en not_active Abandoned
2018
- 2018-05-15 US US15/980,664 patent/US20190040145A1/en not_active Abandoned
2019
- 2019-01-08 US US16/242,850 patent/US20190309077A1/en not_active Abandoned
2020
- 2020-10-14 US US17/070,623 patent/US20210147559A1/en not_active Abandoned
2023
- 2023-10-31 US US18/499,051 patent/US20240124596A1/en active Pending

Also Published As

Publication number	Publication date
EP2423230A1 (en)	2012-02-29
CN101443360A (zh)	2009-05-27
US20210147559A1 (en)	2021-05-20
EP1999152B1 (en)	2012-09-19
CN103641916A (zh)	2014-03-19
RU2008137763A (ru)	2010-05-10
HK1166988A1 (en)	2012-11-16
RU2012157042A (ru)	2014-07-10
SI2423230T1 (sl)	2013-09-30
EP1999152A1 (en)	2008-12-10
CN103641915A (zh)	2014-03-19
WO2007110631A1 (en)	2007-10-04
KR101481844B1 (ko)	2015-01-13
DK2423229T3 (da)	2013-08-05
US20140079708A1 (en)	2014-03-20
ES2424467T3 (es)	2013-10-02
JP5335662B2 (ja)	2013-11-06
BRPI0709259B1 (pt)	2022-05-31
US20150376285A1 (en)	2015-12-31
AU2007231128A1 (en)	2007-10-04
DK1999152T3 (da)	2013-01-14
US8506960B2 (en)	2013-08-13
RU2495050C2 (ru)	2013-10-10
US9085628B2 (en)	2015-07-21
CN101443360B (zh)	2013-11-27
SI1999152T1 (sl)	2013-02-28
PT1999152E (pt)	2013-01-07
RU2639546C2 (ru)	2017-12-21
PL2423230T3 (pl)	2013-10-31
DK2423230T3 (da)	2013-08-05
PT2423230E (pt)	2013-08-26
JP5665894B2 (ja)	2015-02-04
KR20130140186A (ko)	2013-12-23
BRPI0709259A2 (pt)	2011-06-28
US20120141464A1 (en)	2012-06-07
EP2423229B1 (en)	2013-05-08
KR101451546B1 (ko)	2014-10-16
US8263075B2 (en)	2012-09-11
US20240124596A1 (en)	2024-04-18
US20190309077A1 (en)	2019-10-10
CA2647449C (en)	2017-05-16
EP2423230B1 (en)	2013-05-08
CA2647449A1 (en)	2007-10-04
ES2424468T3 (es)	2013-10-02
MX2008012291A (es)	2009-01-12
PL2423229T3 (pl)	2013-09-30
KR20080113262A (ko)	2008-12-29
PT2423229E (pt)	2013-08-22
JP2009533020A (ja)	2009-09-17
JP2013121350A (ja)	2013-06-20
MX348827B (es)	2017-06-30
CN103641915B (zh)	2017-04-12
US20190040145A1 (en)	2019-02-07
ES2395839T3 (es)	2013-02-15
US20090130093A1 (en)	2009-05-21
PL1999152T3 (pl)	2013-05-31
EP2423229A1 (en)	2012-02-29
SI2423229T1 (sl)	2013-09-30

Publication	Publication Date	Title
HK1166989A1 (en)	2012-11-16	Binding member for gm-csf receptor gm-csf
EP2468774A3 (en)	2013-01-02	Antibody neutralizers of human granulocyte macrophage colony stimulating factor
CY2018013I2 (el)	2018-09-05	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1120874T1 (el)	2019-12-11	Συνθεση αντισωματος ιντερλευκινης-13
MY147468A (en)	2012-12-14	High affinity antibodies to human il-6 receptor
WO2010011944A3 (en)	2010-05-06	Protein screeing methods
ZA200902460B (en)	2010-07-28	Antibody molecules which bind IL-17A and IL-17F
EP2604628A3 (en)	2013-08-21	Binding members for interleukin-4 receptor alpha (IL-4R) - 173
NO20071740L (no)	2007-06-01	Humaniserte anti-beta7-antagonister og anvendelser derav
IL209277A (en)	2016-02-29	Antibodies and their antigen-binding segments that bind to the interleukin antibody and interleukin 6 and interleukin 6 receptor complex
HRP20130400T1 (xx)	2013-06-30	Anti-il-23 protutijela, pripravci, postupci i njihova uporaba
LT2486941T (lt)	2017-06-12	Žmogaus antikūnai, kurie jungiasi prie cxcr4, ir jų panaudojimas
ZA200706425B (en)	2014-07-30	Anti-interferon alpha monoclonal antibodies and methods for use
EP2311880A3 (en)	2011-07-27	Cripto binding molecules
IL201281A0 (en)	2010-05-31	Antibodies that bind both il - 17a and il-17f and methods of using the same
EP2327423A3 (en)	2013-05-15	Human antibodies against human interleukin-22 (IL-22)
MX2009003774A (es)	2009-04-22	Anticuerpos para linfotoxina-alfa.
TW200700726A (en)	2007-01-01	Autoantibody detection for cancer diagnostics
HK1154904A1 (zh)	2012-05-04	天然抗體及其抑制劑
CY1114297T1 (el)	2016-08-31	Μελος προσδεσης για gm-csf υποδοχεα
EP1969008A4 (en)	2009-08-12	ANTIBODIES TO INTERLEUKIN-22 BINDING PROTEIN AND ITS APPLICATIONS IN THE TREATMENT OF METABOLISM DISORDERS
ZA200802413B (en)	2009-05-27	Interleukin-13 antibody composition
AU2005906549A0 (en)	2005-12-08	Interleukin 10 receptor alpha and chimeric molecules thereof
UA97232C2 (ru)	2012-01-25	Изолированное антитело, которое связывает моноцитный хемоатрактантный белок 1 (мср-1) человека